You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

PLASMA & BIOTHERAPIES

First patient enrolled and treated in Kedrion’s CARES10 clinical study

Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients

read more 

EVENTS

June 27 and 28 in Trieste (Italy), a two-day event dedicated to hemophilia

Replacement therapy, personalization and access to treatment are the main themes of the congress organized by Kedrion

read more 

EVENTS

16th International Hemophilia Congress in Turkey

A scientific symposium on the prevention and eradication of inhibitors in patients affected by Hemophilia A

read more 
  1. EVENTS - 31-03-2014

    Award in the US for efforts to support hemophilia patients communities

    Kedrion’s Vice-President of North American Commercial Operations is “Man of the Year” for the Hemophilia Association of New Jersey

    read more 
  2. EVENTS - 11-02-2014

    Conference in Colombia: Professor Mannucci on the future of hemophilia

    The event, open to industry experts, patients’ associations and the scientific community, took place in Medellín on February 12th, 2014

    read more 
  3. PLASMA & BIOTHERAPIES - 27-11-2013

    Distribution of the first recombinant Factor VIII from human cells

    Kedrion to be the distributor in Italy over the next ten years. The indication is the treatment of…

    read more 
  4. CORPORATE - 11-11-2013

    Kedrion and La Kelley Communication for a donation in Pakistan

    500,000 IU of Factor IX shipped to the Pakistan Hemophilia Patients Welfare Society Rawalpindi.

    read more 

Pages

For more information please contact: pressoffice@kedrion.com